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Th  e discovery of the angiotensin-converting enzyme 
(ACE) homolog ACE2 [EC 3.4.15.1] has provoked 
intensive eﬀ  orts to elucidate the role of this enzyme in 
various pathologies, including hypertension, diabetes, 
heart failure, viral infection, pulmonary injury and liver 
ﬁ  brosis.  Th  e biological relevance of ACE2 reﬂ  ects  its 
critical location in the enzymatic cascade of the renin–
angiotensin system to directly govern the local expression 
of angiotensin (Ang) II and Ang-(1–7), two bioactive 
hormones with signiﬁ  cant and opposing actions.
In the present issue of Arthritis Research & Th  erapy, 
Takahashi and colleagues assessed circulating levels of 
ACE2 in patients with connective tissue pathologies 
including pulmonary hypertension and persistent digital 
ischemia [1]. In comparison with normal controls, 
patients with overt vasculopathy expressed signiﬁ  cantly 
higher amounts of ACE2 protein in the circulation. Th  ese 
patients, however, exhibited reduced ACE2 activity in 
serum and circulating autoantibodies against the enzyme. 
Th   ere are few reports on the circulating levels of ACE2 in 
humans or experimental models, possibly reﬂ  ecting the 
diﬃ   culty of obtaining a consistent measure  ment of the 
enzymatic activity. Th   e current study reveals a potentially 
novel mechanism to attenuate the catalytic activity of 
ACE2, thereby promoting the inﬂ  ammatory actions of 
Ang II.
ACE and ACE2 are both chloride-activated metallo-
peptidases that are predominantly associated with the 
cell membrane and are widely distributed in various 
tissues and vascular beds. In contrast to ACE, which 
cleaves two amino acid residues from the carboxyl 
terminus of Ang I to form Ang II, ACE2 hydrolyzes a 
single amino acid from the carboxyl end of Ang II to form 
Ang-(1–7) [2]. ACE is considered the primary enzymatic 
pathway that catalyzes the generation of Ang II in the 
circulation and tissues. ACE inhibitors, which have 
become standard therapies in the treatment of hyper-
tension and other cardiovascular disease, have little or no 
inhibitory activity against ACE2, but they reduce the 
metabolism of Ang-(1–7) [2]. Circulating levels of ACE 
activity are readily measurable in humans and other 
species using synthetic substrates or assessing the direct 
conversion of Ang I to Ang II.
In comparison with serum ACE, Rice and colleagues 
reported that the circulating levels of ACE2 were 100-fold 
lower and that <10% (40 out of 494) of their patients 
expressed measurable ACE2 activity [3]. Nevertheless, 
families with detectable circulating ACE2 exhibited a 
greater incidence of cardiovascular pathologies although 
the overall sample population was low. More recent 
studies by Epelman and colleagues ﬁ  nd that circulating 
levels of ACE2 are highly associated with increasing 
severity of progressive heart failure [4]. However, patients 
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angiotensin system including aldosterone antagonists 
which may increase basal ACE2 expression potentially 
contributing to the protective mechanisms of these 
therapies.
Th  ere is increasing evidence for the interplay of the 
renin–angiotensin system and inﬂ  ammatory events [5]. 
Pre-eclampsia is associated with circulating autoanti-
bodies against the AT1 protein that act as functional 
receptor agonists to promote vasoconstriction and inﬂ  am-
mation [5]. Studies by Harrison and colleagues suggest 
that T-cell expression of the AT1 receptor contributes to 
inﬂ   ammatory events and the development of hyper-
tension. Moreover, activated T cells may themselves 
generate Ang II locally to inﬂ  uence cell function in an 
autocrine manner [6]. In experimental encephalo  myelitis, 
AT1 expression was increased and subsequent AT1 
receptor blockade or ACE inhibition ameliorated the 
autoimmune inﬂ  ammation [7].
Th  e present ﬁ   ndings by Takahashi  and colleagues 
reveal increased expression of circulating ACE2 in 
patients with vasculopathy utilizing a novel protein cap-
ture assay [1]. Despite the increased levels of the enzyme, 
ACE2 activity was markedly lower in comparison with 
the control group. Indeed, the authors report the 
presence of circulating levels of ACE2 antibodies that 
exhibit inhibitory activity in vitro. Previous studies 
showed that commercial sources of antibodies against 
ACE2 also inhibit enzyme activity, suggesting the epitope 
may encompass the catalytic site [4]; however, the present 
study is the ﬁ  rst to identify autoantibodies that attenuate 
enzyme activity in a patient population.
Th   e current ﬁ  ndings are of potential importance in our 
understanding of the role of circulating and tissue 
sources of ACE2, particularly in various disease states. 
Increased circulating levels of ACE2 may reﬂ  ect  a 
compensatory mechanism to alter the balance of the 
renin–angiotensin system to favor the ACE2–
Ang-(1–7)–AT7 receptor axis and promote the anti-
ﬁ   brotic and anti-inﬂ   ammatory actions of the hepta-
peptide, as well as attenuate the Ang II–AT1 receptor 
pathway. Clearly, generation of endogenous antibodies 
with inhibitory activity against ACE2 may undermine 
this compensatory response. Indeed, identiﬁ  cation  of 
endo  genous ACE2 inhibitors is important in lieu of 
optimizing the therapeutic beneﬁ  ts following adminis-
tration of recombinant soluble ACE2, as recently 
demonstrated in models of diabetic nephropathy [8] and 
liver ﬁ  brosis [9] or in the genetic expression of ACE2 in 
pulmonary hypertension [10].
Although the ongoing study of the renin–angiotensin 
system has now surpassed the century mark, the 
characterization of this system and identiﬁ  cation of the 
factors that regulate the expression or activity of its 
components continues to yield novel therapeutic targets 
in cardiovascular disease and other pathologies.
Abbreviations
ACE, angiotensin-converting enzyme; Ang, angiotensin.
Acknowledgements
These studies were supported in part by grants from the National Institute of 
Health (HL-56973).
Competing interests
The authors declare that they have no competing interests.
  Published: 28 June 2010
References
1.  Takahashi Y, Haga S, Ishizaka Y, Mimori A: Autoantibodies to angiotensin 
converting enzyme 2 in patients with connective tissue diseases. Arthritis 
Res Ther 2010, 12:R85.
2. Chappell  MC:  Emerging evidence for a functional angiotensin-converting 
enzyme 2-angiotensin-(1-7) mas receptor axis; more than regulation of 
blood pressure? Hypertension 2007, 50:596-599.
3.  Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM: Circulating 
activities of angiotensin-converting enzyme, its homolog, angiotensin-
converting enzyme 2, and neprilysin in a family study. Hypertension 2006, 
48:914-920.
4  Epelman S, Tang WHW, Chen SY, Van Lente F, Francis GS, Sen S: Detection of 
soluble angiotensin-converting enzyme 2 in heart failure: insights into the 
endogenous counter-regulatory pathway of the renin–angiotensin–
aldosterone system. J Am Coll Cardiol 2008, 52:750-754.
5  Verlohren S, Muller DN, Luft FC, Dechend R: Immunology in hypertension, 
preeclampsia, and target-organ damage. Hypertension 2009, 54:439-443.
6.  Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison 
DG: Regulation of T-cell function by endogenously produced angiotensin 
II. Am J Physiol 2009, 296:R208-R216.
7.  Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein 
MJ, Bhat R, Raine CS, Sobel RA, Steinman L: Blocking angiotensin-converting 
enzyme induces potent regulatory T cells and modulates TH1- and TH17-
mediated autoimmunity. Proc Natl Acad Sci U S A 2009, 106:14948-14953.
8.  Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, 
Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW: Human 
recombinant ACE2 reduces the progression of diabetic nephropathy. 
Diabetes 2010, 59:529-538.
9.  Osterreicher CH, Taura K, De Minicis S, Seki E, Penz-Osterreicher M, Kodama Y, 
Kluwe J, Schuster M, Oudit GY, Penninger JM, Brenner DA: Angiotensin-
converting-enzyme 2 inhibits liver fi  brosis in mice. Hepatology 2009, 
50:929-938.
10.  Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, 
Bradford CN, Shenoy V, Oh SP, Katovich MJ, Raizada MK: Prevention of 
pulmonary hypertension by angiotensin-converting enzyme 2 gene 
transfer. Hypertension 2009, 54:365-371.
doi:10.1186/ar3052
Cite this article as: Chappell MC: Angiotensin-converting enzyme 2 
autoantibodies: further evidence for a role of the renin–angiotensin system 
in infl  ammation. Arthritis Research & Therapy 2010, 12:128.
Chappell Arthritis Research & Therapy 2010, 12:128 
http://arthritis-research.com/content/12/3/128
Page 2 of 2